Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

• 1 January 2002
• journal article
• review article
• Published by National Institute for Health and Care Research in Health Technology Assessment
• Vol. 6  (3) , 1-85
• https://doi.org/10.3310/hta6030

Abstract

Keywords

• RITUXIMAB
• FOLLICULAR
• REFRACTORY
• III
• HODGKIN'S
• LYMPHOMA
• PUBLISHED
• LINE TREATMENT

Funding Information

• Health Technology Assessment Programme (00/12/02)